Used primarily in the treatment of certain blood cancers, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It works by inhibiting a specific enzyme called phosphoinositide 3-kinase delta (PI3Kδ), which plays a key role in the survival and spread of malignant B-cells. By blocking this pathway, the drug helps reduce tumor growth and promotes cancer cell death. It is especially beneficial for patients who have relapsed or are resistant to other therapies. The compound has shown effectiveness in reducing lymph node enlargement and improving overall survival in clinical settings. It is taken orally, allowing for convenient outpatient treatment.